Ad5-Ag85A

Drug Profile

Ad5-Ag85A

Alternative Names: Ad5Ag85A; Recombinant genetic TB vaccine Ad5Ag85A; Recombinant-deficient human adenoviral TB vaccine (Ad5Ag85A) - Tianjin CanSino Biotechnology; TB vaccine candidate - Tianjin CanSino Biotechnology/Aeras

Latest Information Update: 13 Apr 2016

Price : $50

At a glance

  • Originator McMaster University
  • Class Antituberculars; DNA vaccines; Gene therapies; Tuberculosis vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Tuberculosis

Most Recent Events

  • 13 Apr 2016 Phase I development is ongoing in Canada
  • 29 Aug 2013 Aeras receives 5-year grant from Department for International Development in the United Kingdom for vaccine development in tuberculosis
  • 08 Aug 2013 McMaster University terminates phase I trial in Tuberculosis (in volunteers, prevention) in Canada (NCT00800670)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top